| |
|
|
Daewoong Pharmaceutical (069620) |
|
|
STOCK |
|
|
|
  |
(unit : Won, Share) |
| Fiscal Year End |
05.03 | 06.03 | 07.03 | 08.03 |
| Par Value |
2,500 | 2,500 | 2,500 | 2,500 |
| Yearly Highest Price |
27,400 | 47,100 | 63,500 | 108,500 |
| Yearly Lowest Price |
17,400 | 21,700 | 29,500 | 50,200 |
| Common Shares O/S |
9,878,538 | 9,878,538 | 9,878,538 | 9,878,538 |
| Preferred Shares O/S |
- | - | - | - |
| Market Cap.(100Mn.Won) |
2,454 | 4,652 | 6,272 | 10,718 |
| Dividends (%) |
27.0 | 28.0 | 32.0 | 32.0 |
|
 |
(Company/Sector/Market) |
| |
2006.12 | 2007.12 |
| Beta |
0.83 / 0.92 / 1.00 | 0.72 / 0.75 / 1.00 |
| Volatility |
39.21 / 24.64 / 18.09 | 36.09 / 24.30 / 22.80 |
|
 |
(unit : Won) |
| Fiscal Year End |
05.03 | 06.03 | 07.03 | 08.03 |
| Earnings Per Share |
2,623 | 3,773 | 5,294 | 6,277 |
| Sales Per Share |
28,419 | 36,212 | 43,689 | 51,534 |
| Book Value Per Share |
14,707 | 17,232 | 21,014 | 26,317 |
| Cash Flow Per Share |
3,063.23 | 3,144.67 | 5,342.01 | 2,810.33 |
|
 |
(Unit : Times) |
| Fiscal Year End |
05.03 | 06.03 | 07.03 | 08.03 |
| Price / Earnings (H/L) |
10.45/6.63 | 12.48/5.75 | 11.99/5.57 | 17.29/8.00 |
| Price / Sales (H/L) |
0.96/0.61 | 1.30/0.60 | 1.45/0.68 | 2.11/0.97 |
| Price / Book (H/L) |
1.86/1.18 | 2.73/1.26 | 3.02/1.40 | 4.12/1.91 |
| Price / Cash Flow (H/L) |
8.94 / 5.68 | 14.98 / 6.90 | 11.89 / 5.52 | 38.61 / 17.86 |
|
 |
(Unit : 100Mn.Won, %) |
| Fiscal Year End |
05.03 |
06.03 |
07.03 |
08.03 |
| Company |
Sector |
Company |
Sector |
Company |
Sector |
Company |
Sector |
| Invested Capital |
1,560 |
756 |
1,759 |
- |
2,050 |
- |
2,342 |
- |
| NOPLAT |
240 |
72 |
349 |
- |
446 |
- |
531 |
- |
| Return on Invested Capital |
15 |
9 |
19 |
- |
21 |
- |
22 |
- |
| WACC |
5 |
6 |
6 |
- |
7 |
- |
6 |
- |
| Economic Value Added |
153.1 |
23.1 |
232.2 |
- |
301.4 |
- |
378.9 |
- |
|
 |
(Unit : 100Mn.Won, Times) |
| Fiscal Year End |
2005.03 | 2006.03 | 2007.03 | 2008.03 |
| Enterprise Value(EV) |
2,454.82 | 4,652.79 | 6,272.87 | 10,718.21 |
| EBITDA |
418.25 | 603.56 | 802.18 | 855.31 |
| EBITDA/Sales |
0.15 | 0.18 | 0.20 | 0.18 |
| EBITDA/Financial Exp. |
10.12 | 16.60 | 18.09 | 57.10 |
| EV/EBITDA |
5.87 | 7.71 | 7.82 | 12.53 |
|
|
|
|
